



# SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 3

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Lorazepam Injection (Hospira, Inc)  
**Product Code(s)** PZ03156  
**Synonyms** PNU-33030  
**Trade Name:** Not applicable  
**Chemical Family:** Benzodiazepine

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as antianxiety agent

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

**Reproductive toxicity**

Category 1B - (H360D, H362)

**Effects on or via lactation**

Yes

### OSHA Classification

**Hazards not otherwise classified (HNOC)**

Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**

Not applicable

### 2.2. Label elements



# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 2 / 13  
Version 3

**Signal word** Danger  
**Hazard statements** H360D - May damage the unborn child  
H362 - May cause harm to breast-fed children

**Precautionary Statements - EU (§28, 1272/2008)** P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P260 - Do not breathe dust/fume/gas/mist/vapors/spray  
P263 - Avoid contact during pregnancy/while nursing  
P264 - Wash hands thoroughly after handling  
P270 - Do not eat, drink or smoke when using this product  
P280 - Wear protective gloves and protective clothing  
P308 + P313 - IF exposed or concerned: Get medical advice/attention  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

**2.3. Other hazards**  
**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**PBT & vPvB** The product does not contain any substance(s) classified as PBT or vPvB.

**Endocrine Disruptor Information** This product does not contain any known or suspected endocrine disruptors.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

**3.1 Substances**  
**Substances** Not applicable

### 3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Propylene glycol (CAS #: 57-55-6)	*		200-338-0	Not classified	Not classified	No data available	No data available
Polyethylene glycol (CAS #: 25322-68-3)	*		Not Listed	Not classified	Not classified	No data available	No data available
BENZYL ALCOHOL (CAS #: 100-51-6)	2		202-859-9 (603-057-00-5)	Acute Tox. 4 (H302) Skin Sens. 1B (H317) Eye Irrit. 2	Not classified	No data available	No data available

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 3 / 13  
Version 3

Lorazepam (CAS #: 846-49-1)	<0.4		212-687-6	(H319) Repr.1B (H360D) Lact. (H362)	Not classified	No data available	No data available
--------------------------------	------	--	-----------	--	----------------	----------------------	----------------------

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Propylene glycol 57-55-6	20000	20800	No data available	No data available	No data available
Polyethylene glycol 25322-68-3	22000	20000	No data available	No data available	No data available
BENZYL ALCOHOL 100-51-6	1200 + 1230	2000	4.178	No data available	No data available
Lorazepam 846-49-1	4500	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

<b>Most important symptoms and effects</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

### 4.3. Indication of any immediate medical attention and special treatment needed

<b>Note to physicians</b>	None.
---------------------------	-------

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 4 / 13  
Version 3

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media** Use extinguishing agent suitable for type of surrounding fire.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Not applicable.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

#### Explosion data

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### 5.3. Advice for firefighters

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 5 / 13  
Version 3

## 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

## 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### BENZYL ALCOHOL

Pfizer OEL TWA-8 Hr: 10 ppm

#### Lorazepam

Pfizer OEL TWA-8 Hr: 5 µg/m<sup>3</sup>

#### Propylene glycol

Ireland

TWA: 10 mg/m<sup>3</sup>; particulate  
TWA: 150 ppm; total vapour and particulates  
TWA: 470 mg/m<sup>3</sup>; total vapour and particulates  
STEL: 1410 mg/m<sup>3</sup> (calculated); particulates  
STEL: 30 mg/m<sup>3</sup> (calculated);  
STEL: 450 ppm (calculated); total vapor and particulates  
TWA: 7 mg/m<sup>3</sup>;  
TWA-NDS: 100 mg/m<sup>3</sup>; vapor and inhalable fraction  
MAC: 7 mg/m<sup>3</sup>  
TWA: 150 ppm; total vapour and particulate  
TWA: 474 mg/m<sup>3</sup>; total vapour and particulate  
TWA: 10 mg/m<sup>3</sup>; particulate  
STEL: 450 ppm; total vapour and particulate  
STEL: 1422 mg/m<sup>3</sup>; total vapour and particulate  
STEL: 30 mg/m<sup>3</sup>; particulate

Latvia

Poland

Russia

United Kingdom

#### Polyethylene glycol

Austria

Denmark

Germany DFG

Germany TRGS

Russia

Slovakia

Switzerland

#### BENZYL ALCOHOL

Bulgaria

Czech Republic

Finland

Germany DFG

TWA-TMW: 1000 mg/m<sup>3</sup>; inhalable fraction  
STEL-KZGW: 4000 mg/m<sup>3</sup> (4 X 15 min); inhalable fraction  
TWA: 1000 mg/m<sup>3</sup>;  
STEL: 2000 mg/m<sup>3</sup>;  
TWA-MAK: 250 mg/m<sup>3</sup>; I(2);inhalable fraction  
Peak: 500 mg/m<sup>3</sup>; inhalable fraction  
TWA-AGW; 200 mg/m<sup>3</sup> (exposure factor 2); inhalable fraction  
MAC: 10 mg/m<sup>3</sup>  
TWA: 1000 mg/m<sup>3</sup>;  
TWA-MAK: 500 mg/m<sup>3</sup>;

TWA: 5.0 mg/m<sup>3</sup>;  
40 mg/m<sup>3</sup>  
Ceiling: 80 mg/m<sup>3</sup>  
TWA: 10 ppm;  
TWA: 45 mg/m<sup>3</sup>;  
TWA-MAK: 22 mg/m<sup>3</sup>; I(2);  
TWA-MAK: 5 ppm; I(2);  
Peak: 44 mg/m<sup>3</sup>;  
Peak: 10 ppm;  
Sk

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 6 / 13  
Version 3

Germany TRGS

TWA-AGW; 5 ppm (exposure factor 2);  
TWA-AGW; 22 mg/m<sup>3</sup> (exposure factor 2);  
Sk

Ceiling Limit Value

25 mg/m<sup>3</sup>

Latvia

TWA: 5 mg/m<sup>3</sup>;

Poland

TWA-NDS: 240 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

Skin

Switzerland

TWA-MAK: 5 ppm; aerosol, vapour

TWA-MAK: 22 mg/m<sup>3</sup>; aerosol, vapour

Sk

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

Physical state

Liquid

Color

Clear, colorless

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 7 / 13  
Version 3

<b>Odor</b>	No information available.
<b>Odor threshold</b>	No information available
<b><u>Property</u></b>	<b><u>Values</u></b>
<b>Melting point / freezing point</b>	No data available
<b>Boiling point or initial boiling point and boiling range</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Lower and upper explosion limit/flammability limit</b>	
Lower explosion limit	No data available
Upper explosion limit	No data available
<b>Flash point</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	
SADT (°C)	No data available
<b>pH</b>	No data available
pH (as aqueous solution)	No data available
<b>Kinematic viscosity</b>	No data available
<b>Dynamic viscosity</b>	No data available
<b>Solubility</b>	No data available Practically insoluble
<b>Vapor pressure</b>	No data available
<b>Density and/or relative density</b>	No data available
Bulk density	No data available
Liquid Density	No data available
<b>Vapor density</b>	No data available
<b>Particle characteristics</b>	
Particle Size	No information available
Particle Size Distribution	No information available

## **9.2. Other information**

<b>Molecular formula</b>	Mixture
<b>Molecular weight</b>	Mixture

### **9.2.1. Information with regard to physical hazard classes**

No information available

### **9.2.2. Other safety characteristics**

No information available

## **Section 10: STABILITY AND REACTIVITY**

### **10.1. Reactivity**

<b>Reactivity</b>	No information available.
-------------------	---------------------------

### **10.2. Chemical stability**

<b>Stability</b>	Stable under normal conditions.
------------------	---------------------------------

#### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### **10.3. Possibility of hazardous reactions**

<b>Possibility of hazardous reactions</b>	No information available.
---	---------------------------

<b>Hazardous polymerization</b>	Will not occur.
---------------------------------	-----------------

### **10.4. Conditions to avoid**

<b>Conditions to avoid</b>	Keep away from heat and other sources of ignition, including electrostatic discharge.
----------------------------	---

### **10.5. Incompatible materials**

<b>Incompatible materials</b>	As a precautionary measure, keep away from strong oxidizers.
-------------------------------	--

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 8 / 13  
Version 3

## 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

<b>General Information:</b>	The information included in this section describes the potential hazards of the individual ingredients
<b>Short term</b>	May be harmful if swallowed. May cause irritation (based on components).
<b>Long Term:</b>	Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus. May cause harm to breastfed babies.
<b>Known Clinical Effects:</b>	Adverse effects most commonly reported in clinical use include sedation, dizziness, weakness, clumsy motion of limbs/trunk (ataxia), incoordination, tiredness, drowsiness, amnesia, confusion, state of intense good feeling (euphoria), suicidal behavior. Benzodiazepines may cause fetal damage when administered during pregnancy. Secreted in human breast milk.
<b>Acute toxicity</b>	Based on available data, the classification criteria are not met.
<b>Serious eye damage/eye irritation</b>	Based on available data, the classification criteria are not met.
<b>Skin corrosion/irritation</b>	Based on available data, the classification criteria are not met.
<b>Respiratory or skin sensitization</b>	Based on available data, the classification criteria are not met.
<b>STOT - single exposure</b>	Based on available data, the classification criteria are not met.
<b>STOT - repeated exposure</b>	Based on available data, the classification criteria are not met.
<b>Reproductive toxicity</b>	May damage the unborn child.
<b>Germ cell mutagenicity</b>	Based on available data, the classification criteria are not met.
<b>Carcinogenicity</b>	Based on available data, the classification criteria are not met.
<b>Aspiration hazard</b>	Based on available data, the classification criteria are not met.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Propylene glycol

Rat Oral LD 50 22,000 mg/kg  
Mouse Oral LD 50 24,900 mg/kg  
Rabbit Dermal LD 50 20,800 mg/kg

#### BENZYL ALCOHOL

Rat Oral LD 50 1230 mg/kg  
Mouse Oral LD 50 1360 mg/kg  
Rabbit Dermal LD 50 2 gm/kg

#### Lorazepam

Mouse Oral LD 50 1850 mg/kg  
Rat IV LD50 20(M) 25 (F) mg/kg  
Dog IV LD50 50 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Propylene glycol	= 20 g/kg ( Rat )	= 20800 mg/kg ( Rabbit )	-
Polyethylene glycol	= 22 g/kg ( Rat )	> 20 g/kg ( Rabbit )	-
BENZYL ALCOHOL	= 1230 mg/kg ( Rat )	= 2 g/kg ( Rabbit )	> 4178 mg/m <sup>3</sup> ( Rat ) 4 h
Lorazepam	= 4500 mg/kg ( Rat )	-	-

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.



# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 9 / 13  
Version 3

## Irritation / Sensitization: (Study Type, Species, Severity)

### Propylene glycol

Skin irritation Rabbit Mild  
Eye irritation Rabbit Mild

### Polyethylene glycol

Eye Irritation Rabbit Mild  
Skin Irritation Rabbit Mild

### BENZYL ALCOHOL

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Minimal  
Skin Irritation Guinea Pig Moderate

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

### Lorazepam

1 Month(s) Rat Intravenous 10 mg/kg/day NOAEL Blood, Spleen

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Lorazepam

Fertility and Embryonic Development Rabbit Intravenous 40 mg/kg/day LOAEL Fetotoxicity  
Embryo / Fetal Development Rat Intravenous 2 mg/kg/day LOAEL Maternal Toxicity, Not Teratogenic  
Embryo / Fetal Development Rabbit Intravenous 1 mg/kg/day LOAEL Maternal Toxicity, Not Teratogenic

## Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Lorazepam

18 Month(s) Rat Oral Not carcinogenic  
18 Month(s) Mouse Oral Not carcinogenic

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

## Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

### BENZYL ALCOHOL

*Pimephales promelas* (Fathead Minnow) EPA LC50 96 hours 460 - 770 mg/L  
*Daphnia magna* (Water Flea) NPDES OECD EC50 48 Hours 230 mg/L  
*Pseudokirchneriella subcapitata* (Green Alga) OECD EC50 72 hours 500 mg/L

### 12.2. Persistence and degradability

**Persistence and degradability**

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 10 / 13  
Version 3

## **Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)**

### **BENZYL ALCOHOL**

OECD Activated sludge Ready 92 % After 28 Day(s) Ready

## **12.3. Bioaccumulative potential**

**Bioaccumulation** No information available.

## **12.4. Mobility in soil**

**Mobility in soil** No information available.

## **12.5. Results of PBT and vPvB assessment**

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Propylene glycol	Not PBT/vPvB PBT assessment does not apply
Polyethylene glycol	Not PBT/vPvB
BENZYL ALCOHOL	Not PBT/vPvB

## **12.6. Endocrine disrupting properties**

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## **12.7. Other adverse effects**

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## **Section 13: DISPOSAL CONSIDERATIONS**

### **13.1. Waste treatment methods**

#### **Waste from residues/unused products**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## **Section 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

**UN number:** Not applicable

**UN proper shipping name:** Not applicable

**Transport hazard class(es):** Not applicable

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 11 / 13  
Version 3

Packing group: Not applicable  
Environmental Hazard(s): Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Propylene glycol

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-338-0
AICS	Present

Polyethylene glycol

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 3 Schedule 2

BENZYL ALCOHOL

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-859-9
AICS	Present

Lorazepam

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Developmental
U.S. - DEA (Drug Enforcement Administration)	Schedule IV Controlled Substance
EINECS	212-687-6
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

### National regulations

Chemical name	French RG number
Propylene glycol 57-55-6	RG 84
BENZYL ALCOHOL 100-51-6	RG 84

### Germany

#### Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905 Not applicable

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 12 / 13  
Version 3

## Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable  
**Storage of Hazardous Material** Not applicable  
**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable  
**Major Accidents Ordinance SR 814.012** Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### **Authorizations and/or restrictions on use:**

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
BENZYL ALCOHOL 100-51-6	75	-

## **Persistent Organic Pollutants**

Not applicable

## **Ozone-depleting substances (ODS) Regulation (EU) 2024/590**

Not applicable.

## **Explosives Precursors Marketing and Use (2019/1148)**

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing Chemicals Inventory  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## **15.2. Chemical safety assessment**

**Chemical Safety Report** No information available

## **Section 16: OTHER INFORMATION**

### **Key or legend to abbreviations and acronyms used in the safety data sheet**

### **Full text of any hazard and/or precautionary statements referred to under Sections 2-15**

H360D - May damage the unborn child H362 - May cause harm to breast-fed children H302 - Harmful if swallowed H332 - Harmful if inhaled

# SAFETY DATA SHEET

Product Name Lorazepam Injection (Hospira, Inc)  
Revision date 17-Jun-2025

Page 13 / 13  
Version 3

---

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.

**Reason for revision** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

**Revision date** 17-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**